<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 381 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page380.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=381">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 381 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 381</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=381"><img src="../thumb/381.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Volume 60 Number 4                                                     April 2020
                                                                                        NJ, USA. All rights reserved. ZA-CXB-00008 04/21
                                                                                        60 mg – 37/3.1/0399, 90 mg – 37/3.1/0400, 120 mg – 37/3.1/0401. Each ARCOXIA tablet contains 30 mg, 60 mg, 90 mg or 120 mg of etoricoxib. Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth,
                                                                                        S3  EXINEF – Reg. No’s: 30 mg – 44/3.1/0898, 60 mg – 44/3.1/0899, 90 mg – 44/3.1/0900, 120 mg – 44/3.1/0901. Each EXINEF tablet contains 30 mg, 60 mg, 90 mg or 120 mg of etoricoxib.  S3  ARCOXIA – Reg. No’s: 30 mg – 44/3.1/0063,
                                                                              Private Bag 3, Halfway House, 1685. Tel: 011 655 3000. www.msd.co.za
                               approved by the Medicines Regulatory Authority.
                                                                              MSD (Pty) Ltd (Reg. No. 1996/003791/07),
                                    For full prescribing information refer to the package insert
                                                                                        hypertension, gastrointestinal disorders (e.g. abdominal pain, ﬂ  atulence, heartburn), diarrhoea, dyspepsia, epigastric discomfort, nausea, ecchymosis, asthenia/fatigue, ﬂ  u-like disease, increased ALT, AST.
                                                                                        attempting to conceive. SIDE EFFECTS: In clinical studies, the undesirable effects proﬁ  le was similar in patients with OA or RA treated with EXINEF for one year or longer. Very common (≥ 1/10) and Common (≥ 1/100, &lt; 1/10) reported effects: alveolar osteitis, oedema/ﬂ  uid retention, dizziness, headache, palpitations,
                                                                                        90 mg daily. EXINEF may mask fever and other signs of inﬂ  ammation or infection. EXINEF Tablets contain lactose. Patients with hereditary problems of galactose intolerance, the Lapp lactase deﬁ  ciency or glucose-galactose malabsorption should not take EXINEF. The use of EXINEF is not recommended in fertile women
                                                                                        concomitantly with aspirin (even at low doses). Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (approximately 3 or more times the upper limit of normal) have been reported in approximately 1 % of patients in clinical trials treated for up to one year with EXINEF 60 and
                                                                                        deteriorate during treatment, appropriate measures should be taken, including discontinuation of EXINEF. Upper GI complications, some of them resulting in fatal outcome, have occurred in patients treated with EXINEF. There is an increase in the risk of gastrointestinal adverse effects when EXINEF is taken
                                                                                                                                                                                    April 2020
                                                                                        careful consideration. EXINEF is not a substitute for aspirin for cardiovascular prophylaxis because of its lack of effect on platelets. When using EXINEF in the elderly and in patients with renal, hepatic or cardiac dysfunction, medically appropriate supervision should be intensiﬁ  ed. If these patients
                                                                                        may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. Patients with signiﬁ  cant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with EXINEF after
                                                                                        pressure monitoring during treatment with EXINEF. Clinical trials suggest that the selective COX-2 inhibitor class of medicines such as EXINEF are associated with an increased risk of thrombotic events (especially myocardial infarction (MI) and stroke). As the cardiovascular risks of selective COX-2 inhibitors
                                                                                                                                                                             New Product Launches:
                                                                                        when initiating treatment with EXINEF in patients with dehydration. Fluid retention, oedema and hypertension have been observed in patients taking EXINEF. All NSAIDs, including EXINEF, can be associated with new onset or recurrent congestive cardiac failure. Special attention should be paid to blood
                                                                                        such as EXINEF has resulted in renal papillary necrosis and other renal injury. Under conditions of compromised renal perfusion, administration of EXINEF may cause a reduction in prostaglandin formation and, secondarily, in renal blood ﬂ  ow and thereby impair renal function. Caution should be used
                                                                                        cerebrovascular disease; perioperative analgesia in the setting of coronary artery bypass surgery (CABG). WARNINGS AND SPECIAL PRECAUTIONS: EXINEF may predispose to cardiovascular events, gastrointestinal events or cutaneous reactions which may be fatal. Long-term administration of NSAIDs
                                                                                        hypertension which has not been adequately controlled; pregnancy and lactation; children and adolescents under 16 years of age; patients with inﬂ  ammatory bowel disease; patients with congestive heart failure (NYHA II - IV); established ischaemic heart disease, peripheral arterial disease and/or
                                                                                                                                                                          Xinoct (15.1) .............................................. 198
                                                                                        or serum albumin &lt; 25 g/l); patients with estimated creatinine clearance &lt; 30 ml/min; patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioedema or urticaria following the administration of aspirin or other non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) including EXINEF;
                                                                                        SELECTED SAFETY INFORMATION:  CONTRAINDICATIONS: EXINEF is contraindicated in: patients with known hypersensitivity to any of the excipients of EXINEF; patients with active peptic ulceration or gastrointestinal (GI) bleeding; patients with severe hepatic dysfunction (Child-Pugh score &gt; 9
                                                                                         Postoperative Dental Pain Model. Clin J Pain. 2011;27(1):1–8.  10. Matsumoto AK, Melian A, Mandel DR, et al. for Etoricoxib Rheumatoid Arthritis Study Group. A randomised, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29(8):1623–1630.
                                                                                                                Monthly Index of Medical Specialities
                                                                                         2007;46:496–507.  8. Van der Heijde D, Baraf HSB, Ramos-Remus C, et al. Evaluation of the Efﬁ  cacy of Etoricoxib in Ankylosing Spondylitis. Arthritis & Rheumatism. 2005;52(4):1205-1215.  9. Daniels SE, Bandy DP, Christensen SE, et al. Evaluation of the Dose Range of Etoricoxib in an Acute Pain Setting Using the
                                                                                         placebo-controlled phase III study. Curr Med Res Opin. 2012;28(8):1323-1335.  7. Bingham CO, Sebba AI, Rubin BR, et al. Efﬁ  cacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology.
                                                                                         acid in the treatment of primary dysmenorrhoea: A randomised comparative trial. Journal of Obstetrics and Gynaecology. 2008;28(4):424-426.  6. Viscusi ER, Frenkl TL, Hartrick CT, et al. Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized,
                                                                                         Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-379.  5. Nor Azlin MI, Maryasalwati I, Norzilawati MN, et al. The efficacy of etoricoxib vs mefenamic
                                                                                                                Includes Active Ingredient & Trade Name Indices
                                                                                         REFERENCES: 1. Approved ARCOXIA package insert, October 2013.  2. Approved EXINEF package insert, November 2014.  3. Lin H-Y, Cheng T-T, Wang J-H, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144-150.  4. Moore RA, Moore OA,
                                                                                                                   Tamoltra Mims OFC Mar2020.pdf   1   2020/03/19   12:52
                                                              IN PATIENTS ≥ 16 YEARS OF AGE
                                    2
                                                                                 APPROVED FOR A BROAD RANGE OF INDICATIONS
       1-10
                                        Excellence in Efficacy






                                                                                                       C
                                                                                                       M
                                                                                                       Y
                                                                                                       CM
                                                                                                       MY
                                                                                                       CY
         1,2
                                                                                         Trust the science behind the original etoricoxib…
                                                                                                       CMY
                                                                                                       K

                                                                   ü Active Ingredient

                                                                ü Trade Name
                                                                                      Two select indices listing products by:
                                                                                                    April 2020



                                                                                                      MIMS  Volume 60 No 4

                                                                                                                                                                             TRAMADOL HYDROCHLORIDE 37,5 mg / PARACETAMOL 325 mg
                                                                                                               For further product information contact PHARMA DYNAMICS   P O Box 30958 Tokai Cape Town 7966   Tel +27 21 707 7000
                                                 INDICES
                                                                                                               Fax +27 21 701 5898   Email info@pharmadynamics.co.za   CUSTOMER CARE LINE 0860 PHARMA (742 762)   www.pharmadynamics.co.za
                                                                                                               TAMOLTRA. Each tablet contains tramadol hydrochloride 37,5 mg and paracetamol 325,0 mg.  S5  A46/2.9/0976. 1. Dhillon S. Tramadol/paracetamol; ﬁxed-dose combination: a review of its use in the
                                                                                                               management of moderate to severe pain. Clin Drug Investig. 2010;30(10):711-38. For full prescribing information, refer to the professional information approved by SAHPRA, 27 July 2017. TMB488/03/2019.
                                                                                         Volume 60 Number 4
                     April 2020</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page380.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>&nbsp;&nbsp;&nbsp;<a href="page380.html">380</a>&nbsp;&nbsp;&nbsp;<a href="page381.html">381</a>&nbsp;&nbsp;&nbsp;<a href="page382.html">382</a>&nbsp;&nbsp;&nbsp;<a href="page383.html">383</a>&nbsp;&nbsp;&nbsp;<a href="page384.html">384</a>&nbsp;&nbsp;&nbsp;<a href="page385.html">385</a>&nbsp;&nbsp;&nbsp;<a href="page386.html">386</a>
             </td>
             <td width="35%"><a href="page382.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page382.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
